-
2
-
-
0021323238
-
The basic mechanism of inotropic action of digitalis glycosides
-
Smith TW. The basic mechanism of inotropic action of digitalis glycosides. J Pharmacol 1984; 15 Suppl 1: 35-51.
-
(1984)
J Pharmacol
, vol.15
, pp. 35-51
-
-
Smith, T.W.1
-
4
-
-
0038621773
-
Structure and mechanism of Na, K-ATPase: Functional sites and their interactions
-
Jorgensen PL, Hakansson KO, Karlish SJ. Structure and mechanism of Na, K-ATPase: functional sites and their interactions. Annu Rev Physiol 2003; 65: 817-49.
-
(2003)
Annu Rev Physiol
, vol.65
, pp. 817-849
-
-
Jorgensen, P.L.1
Hakansson, K.O.2
Karlish, S.J.3
-
5
-
-
0034773778
-
The functional role of beta subunits in oligomeric Ptype ATPases
-
Geering K. The functional role of beta subunits in oligomeric Ptype ATPases. J Bioenerg Biomembr 2001; 33: 425-38.
-
(2001)
J Bioenerg Biomembr
, vol.33
, pp. 425-438
-
-
Geering, K.1
-
7
-
-
0033550055
-
Functional characterization of a testes-specific alpha-subunit isoform of the sodium/potassium adenosinetriphosphatase
-
Blanco G, Melton RJ, Sánchez G, Mercer RW. Functional characterization of a testes-specific alpha-subunit isoform of the sodium/potassium adenosinetriphosphatase. Biochemistry 1999; 38: 13661-9.
-
(1999)
Biochemistry
, vol.38
, pp. 13661-13669
-
-
Blanco, G.1
Melton, R.J.2
Sánchez, G.3
Mercer, R.W.4
-
8
-
-
28644447041
-
Na, K-ATPase subunit heterogeneity as a mechanism for tissue-specific ion regulation
-
Blanco G. Na, K-ATPase subunit heterogeneity as a mechanism for tissue-specific ion regulation. Semin Nephrol 2005; 25: 292-303.
-
(2005)
Semin Nephrol
, vol.25
, pp. 292-303
-
-
Blanco, G.1
-
9
-
-
0033898109
-
Na+, K+-ATPase isozyme diversity; comparative biochemistry and physiological implications of novel functional interactions
-
Mobasheri A, Avila J, Cózar-Castellano I, et al. Na+, K+-ATPase isozyme diversity; comparative biochemistry and physiological implications of novel functional interactions. Biosci Rep 2000; 20: 51-91.
-
(2000)
Biosci Rep
, vol.20
, pp. 51-91
-
-
Mobasheri, A.1
Avila, J.2
Cózar-Castellano, I.3
-
10
-
-
38349140152
-
Structures of the FXYD regulatory proteins in lipid micelles and membranes
-
Franzin CM, Gong XM, Teriete P, Marassi FM. Structures of the FXYD regulatory proteins in lipid micelles and membranes. J Bioenerg Biomembr 2007; 39: 379-383.
-
(2007)
J Bioenerg Biomembr
, vol.39
, pp. 379-383
-
-
Franzin, C.M.1
Gong, X.M.2
Teriete, P.3
Marassi, F.M.4
-
11
-
-
0035282170
-
Functional properties of Na, K-ATPase, and their structural implications, as detected with biophysical techniques
-
Apell HJ, Karlish SJ. Functional properties of Na, K-ATPase, and their structural implications, as detected with biophysical techniques. J Membr Biol 2001; 180: 1-9.
-
(2001)
J Membr Biol
, vol.180
, pp. 1-9
-
-
Apell, H.J.1
Karlish, S.J.2
-
12
-
-
33846783324
-
The Na, K-ATPase receptor complex: Its organization and membership
-
Pierre SV, Xie Z. The Na, K-ATPase receptor complex: its organization and membership. Cell Biochem Biophys 2006; 46: 303-16.
-
(2006)
Cell Biochem Biophys
, vol.46
, pp. 303-316
-
-
Pierre, S.V.1
Xie, Z.2
-
14
-
-
79954415607
-
Structural insights into the high affinity binding of cardiotonic steroids to the Na+, K+-ATPase
-
Yatime L, Laursen M, Morth JP, et al. Structural insights into the high affinity binding of cardiotonic steroids to the Na+, K+-ATPase. J Struct Biol 2011; 174: 296-306.
-
(2011)
J Struct Biol
, vol.174
, pp. 296-306
-
-
Yatime, L.1
Laursen, M.2
Morth, J.P.3
-
15
-
-
84885654984
-
Crystal structure of a Na+-bound Na+, K+-ATPase preceding the E1P state
-
Kanai R, Ogawa H, Vilsen B, et al. Crystal structure of a Na+-bound Na+, K+-ATPase preceding the E1P state. Nature 2013; 502: 201-6.
-
(2013)
Nature
, vol.502
, pp. 201-206
-
-
Kanai, R.1
Ogawa, H.2
Vilsen, B.3
-
16
-
-
69549106325
-
Crystal structure of the sodium-potassium pump (Na+, K+-ATPase) with bound potassium and ouabain
-
Ogawa H, Shinoda T, Cornelius F, Toyoshima C. Crystal structure of the sodium-potassium pump (Na+, K+-ATPase) with bound potassium and ouabain. Proc Natl Acad Sci USA 2009; 106: 13742-7.
-
(2009)
Proc Natl Acad Sci USA
, vol.106
, pp. 13742-13747
-
-
Ogawa, H.1
Shinoda, T.2
Cornelius, F.3
Toyoshima, C.4
-
17
-
-
66249147196
-
Crystal structure of the sodium-potassium pump at 2. 4 A resolution
-
Shinoda T, Ogawa H, Cornelius F, Toyoshima C. Crystal structure of the sodium-potassium pump at 2. 4 A resolution. Nature 2009; 459: 446-50.
-
(2009)
Nature
, vol.459
, pp. 446-450
-
-
Shinoda, T.1
Ogawa, H.2
Cornelius, F.3
Toyoshima, C.4
-
18
-
-
0018088023
-
Alteration of sodium transport in mouse mammary epithelium associated with neoplastic transformation
-
Shen SS, Hamamoto ST, Bern HA, Steinhardt RA. Alteration of sodium transport in mouse mammary epithelium associated with neoplastic transformation. Cancer Res 1978; 38: 1356-61.
-
(1978)
Cancer Res
, vol.38
, pp. 1356-1361
-
-
Shen, S.S.1
Hamamoto, S.T.2
Bern, H.A.3
Steinhardt, R.A.4
-
19
-
-
0022566579
-
Properties of Na+/K+ ATPase and alkaline phosphatase alter during spontaneous and radiation-induced leukemogenesis in mice
-
Gonta-Grabiec K, Rossowski W, Szumiel I. Properties of Na+/K+ ATPase and alkaline phosphatase alter during spontaneous and radiation-induced leukemogenesis in mice. Neoplasma 1986; 33: 141-55.
-
(1986)
Neoplasma
, vol.33
, pp. 141-155
-
-
Gonta-Grabiec, K.1
Rossowski, W.2
Szumiel, I.3
-
20
-
-
0020025086
-
Cardiac glycosides and breast cancer, revisited
-
Stenkvist B, Bengtsson E, Dahlqvist B, et al. Cardiac glycosides and breast cancer, revisited. N Engl J Med 1982; 306: 484.
-
(1982)
N Engl J Med
, vol.306
, pp. 484
-
-
Stenkvist, B.1
Bengtsson, E.2
Dahlqvist, B.3
-
21
-
-
68849107545
-
Oleandrin-mediated inhibition of human tumor cell proliferation: Importance of Na, KATPase alpha subunits as drug targets
-
Yang P, Menter DG, Cartwright C, et al. Oleandrin-mediated inhibition of human tumor cell proliferation: importance of Na, KATPase alpha subunits as drug targets. Mol Cancer Ther 2009; 8: 2319-28.
-
(2009)
Mol Cancer Ther
, vol.8
, pp. 2319-2328
-
-
Yang, P.1
Menter, D.G.2
Cartwright, C.3
-
22
-
-
0034886564
-
Cardenolides and cancer
-
Stenkvist B. Cardenolides and cancer. Anticancer Drugs 2001; 12: 635-8.
-
(2001)
Anticancer Drugs
, vol.12
, pp. 635-638
-
-
Stenkvist, B.1
-
23
-
-
3042611499
-
Digitoxin medication and cancer; case control and internal dose-response studies
-
Haux J, Klepp O, Spigset O, Tretli S. Digitoxin medication and cancer; case control and internal dose-response studies. BMC Cancer 2001; 1: 11.
-
(2001)
BMC Cancer
, vol.1
, pp. 11
-
-
Haux, J.1
Klepp, O.2
Spigset, O.3
Tretli, S.4
-
24
-
-
79959922456
-
A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment
-
Platz EA, Yegnasubramanian S, Liu JO, et al. A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment. Cancer Discov 2011; 1: 68-77.
-
(2011)
Cancer Discov
, vol.1
, pp. 68-77
-
-
Platz, E.A.1
Yegnasubramanian, S.2
Liu, J.O.3
-
25
-
-
84875067038
-
Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study
-
Niraula S, Pond G, De Wit R, et al. Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study. Can Urol Assoc J 2013; 7(1-2): E74-81.
-
(2013)
Can Urol Assoc J
, vol.7
, Issue.1-2
, pp. 74-81
-
-
Niraula, S.1
Pond, G.2
De Wit, R.3
-
26
-
-
84875067038
-
Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study
-
Niraula S, Pond G, de Wit R, et al. Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study. Can Urol Assoc J 2013; 7: E74-81.
-
(2013)
Can Urol Assoc J
, vol.7
, pp. 74-81
-
-
Niraula, S.1
Pond, G.2
de Wit, R.3
-
27
-
-
84864128654
-
Cardiac glycosides exert anticancer effects by inducing immunogenic cell death
-
143ra199
-
Menger L, Vacchelli E, Adjemian S, et al. Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci Transl Med 2012; 4: 143ra199.
-
(2012)
Sci Transl Med
, vol.4
-
-
Menger, L.1
Vacchelli, E.2
Adjemian, S.3
-
28
-
-
63849286667
-
Digoxin treatment is associated with an increased incidence of breast cancer: A population-based case-control study
-
Ahern TP, Lash TL, Sørensen HT, Pedersen L. Digoxin treatment is associated with an increased incidence of breast cancer: a population-based case-control study. Breast Cancer Res 2008; 10: R102.
-
(2008)
Breast Cancer Res
, vol.10
-
-
Ahern, T.P.1
Lash, T.L.2
Sørensen, H.T.3
Pedersen, L.4
-
29
-
-
79957962089
-
Digoxin use and the risk of breast cancer in women
-
Biggar RJ, Wohlfahrt J, Oudin A, et al. Digoxin use and the risk of breast cancer in women. J Clin Oncol 2011; 29: 2165-70.
-
(2011)
J Clin Oncol
, vol.29
, pp. 2165-2170
-
-
Biggar, R.J.1
Wohlfahrt, J.2
Oudin, A.3
-
30
-
-
84861577948
-
Digoxin use and the risk of cancers of the corpus uteri, ovary and cervix
-
Biggar RJ, Wohlfahrt J, Melbye M. Digoxin use and the risk of cancers of the corpus uteri, ovary and cervix. Int J Cancer 2012; 131: 716-21.
-
(2012)
Int J Cancer
, vol.131
, pp. 716-721
-
-
Biggar, R.J.1
Wohlfahrt, J.2
Melbye, M.3
-
31
-
-
0038380368
-
Multiplex gene expression analysis for high-throughput drug discovery: Screening and analysis of compounds affecting genes overexpressed in cancer cells
-
Johnson PH, Walker RP, Jones SW, et al. Multiplex gene expression analysis for high-throughput drug discovery: screening and analysis of compounds affecting genes overexpressed in cancer cells. Mol Cancer Ther 2002; 1: 1293-304.
-
(2002)
Mol Cancer Ther
, vol.1
, pp. 1293-1304
-
-
Johnson, P.H.1
Walker, R.P.2
Jones, S.W.3
-
32
-
-
58149374576
-
Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth
-
Zhang H, Qian DZ, Tan YS, et al. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci USA 2008; 105: 19579-86.
-
(2008)
Proc Natl Acad Sci USA
, vol.105
, pp. 19579-19586
-
-
Zhang, H.1
Qian, D.Z.2
Tan, Y.S.3
-
33
-
-
84863275539
-
Quantitative high-throughput drug screening identifies novel classes of drugs with anticancer activity in thyroid cancer cells: Opportunities for repurposing
-
Zhang L, He M, Zhang Y, et al. Quantitative high-throughput drug screening identifies novel classes of drugs with anticancer activity in thyroid cancer cells: opportunities for repurposing. J Clin Endocrinol Metab 2012; 97: E319-328.
-
(2012)
J Clin Endocrinol Metab
, vol.97
, pp. 319-328
-
-
Zhang, L.1
He, M.2
Zhang, Y.3
-
34
-
-
0036670678
-
Selective cytotoxicity evaluation in anticancer drug screening of fractionated plant extracts
-
Lindholm P, Gullbo J, Claeson P, et al. Selective cytotoxicity evaluation in anticancer drug screening of fractionated plant extracts. J Biomol Screen 2002; 7: 333-40.
-
(2002)
J Biomol Screen
, vol.7
, pp. 333-340
-
-
Lindholm, P.1
Gullbo, J.2
Claeson, P.3
-
35
-
-
66149142810
-
Inhibition of the sodium potassium adenosine triphosphatase pump sensitizes cancer cells to anoikis and prevents distant tumor formation
-
Simpson CD, Mawji IA, Anyiwe K, et al. Inhibition of the sodium potassium adenosine triphosphatase pump sensitizes cancer cells to anoikis and prevents distant tumor formation. Cancer Res 2009; 69: 2739-47.
-
(2009)
Cancer Res
, vol.69
, pp. 2739-2747
-
-
Simpson, C.D.1
Mawji, I.A.2
Anyiwe, K.3
-
37
-
-
84862299900
-
Modulators of Na/K-ATPase: A patent review
-
Wang HY, O'Doherty GA. Modulators of Na/K-ATPase: a patent review. Expert Opin Ther Pat 2012; 22: 587-605.
-
(2012)
Expert Opin Ther Pat
, vol.22
, pp. 587-605
-
-
Wang, H.Y.1
O'Doherty, G.A.2
-
38
-
-
77953482802
-
Selectivity of digitalis glycosides for isoforms of human Na, K-ATPase
-
Katz A, Lifshitz Y, Bab-Dinitz E, et al. Selectivity of digitalis glycosides for isoforms of human Na, K-ATPase. J Biol Chem 2010; 285: 19582-92.
-
(2010)
J Biol Chem
, vol.285
, pp. 19582-19592
-
-
Katz, A.1
Lifshitz, Y.2
Bab-Dinitz, E.3
-
39
-
-
2342487353
-
Na+-K+-ATPase-mediated signal transduction: From protein interaction to cellular function
-
Xie Z, Cai T. Na+-K+-ATPase-mediated signal transduction: from protein interaction to cellular function. Mol Interv 2003; 3: 157-68.
-
(2003)
Mol Interv
, vol.3
, pp. 157-168
-
-
Xie, Z.1
Cai, T.2
-
40
-
-
84899493792
-
Digitalis-induced cell signaling by the sodium pump: On the relation of Src to Na(+)/K(+)-ATPase
-
Gable ME, Abdallah SL, Najjar SM, et al. Digitalis-induced cell signaling by the sodium pump: on the relation of Src to Na(+)/K(+)-ATPase. Biochem Biophys Res Commun 2014; 446: 1151-4.
-
(2014)
Biochem Biophys Res Commun
, vol.446
, pp. 1151-1154
-
-
Gable, M.E.1
Abdallah, S.L.2
Najjar, S.M.3
-
42
-
-
84874941459
-
Cardiotonic steroids-mediated Na+/K+-ATPase targeting could circumvent various chemoresistance pathways
-
Mijatovic T, Kiss R. Cardiotonic steroids-mediated Na+/K+-ATPase targeting could circumvent various chemoresistance pathways. Planta Med 2013; 79: 189-98.
-
(2013)
Planta Med
, vol.79
, pp. 189-198
-
-
Mijatovic, T.1
Kiss, R.2
-
43
-
-
0021808886
-
Pharmacokinetics, bioavailability and serum levels of cardiac glycosides
-
Smith TW. Pharmacokinetics, bioavailability and serum levels of cardiac glycosides. J Am Coll Cardiol 1985; 5: 43A-50A.
-
(1985)
J Am Coll Cardiol
, vol.5
, pp. 43-50
-
-
Smith, T.W.1
-
44
-
-
16344369879
-
Digoxin inhibits neuroblastoma tumor growth in mice
-
Svensson A, Azarbayjani F, Bäckman U, et al. Digoxin inhibits neuroblastoma tumor growth in mice. Anticancer Res 2005; 25: 207-12.
-
(2005)
Anticancer Res
, vol.25
, pp. 207-212
-
-
Svensson, A.1
Azarbayjani, F.2
Bäckman, U.3
-
45
-
-
77949524121
-
Cardiac glycosides induce cell death in human cells by inhibiting general protein synthesis
-
Perne A, Muellner MK, Steinrueck M, et al. Cardiac glycosides induce cell death in human cells by inhibiting general protein synthesis. PLoS One 2009; 4: e8292.
-
(2009)
PLoS One
, vol.4
-
-
Perne, A.1
Muellner, M.K.2
Steinrueck, M.3
-
46
-
-
84904479799
-
Steroidal Cardiac Na+/K+ ATPase Inhibitors Exhibit Strong Anti-Cancer Potential in vitro and in Prostate and Lung Cancer Xenografts in vivo
-
Dimas K, Papadopoulou N, Baskakis C, et al. Steroidal Cardiac Na+/K+ ATPase Inhibitors Exhibit Strong Anti-Cancer Potential in vitro and in Prostate and Lung Cancer Xenografts in vivo. Anticancer Agents Med Chem 2014; 14(5): 762-70.
-
(2014)
Anticancer Agents Med Chem
, vol.14
, Issue.5
, pp. 762-770
-
-
Dimas, K.1
Papadopoulou, N.2
Baskakis, C.3
-
47
-
-
79251547998
-
-
June 1-5, Chicago, Illinois, 2007; (ASCO) ASoCO, suppl; Abstr 8573
-
Khan MI, Taft B, Rasku MA, et al. A phase II trial of biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, interferon and digoxin in melanoma patients: Annual Meeting, June 1-5, Chicago, Illinois, 2007; (ASCO) ASoCO, Vol. 25: 2007; pp suppl; Abstr 8573.
-
(2007)
A phase II trial of biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, interferon and digoxin in melanoma patients: Annual Meeting
, vol.25
-
-
Khan, M.I.1
Taft, B.2
Rasku, M.A.3
-
48
-
-
79251547998
-
-
May 30-June 3, Chicago, 2008; (ASCO) ASoCO, Vol, 26: pp suppl; Abstr 20021
-
Khan MI, Laber D, Chesney J, et al. A phase II trial of biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, interferon and digoxin in melanoma patients: Annual Meeting, May 30-June 3, Chicago, 2008; (ASCO) ASoCO, Vol. 26: 2008; pp suppl; Abstr 20021.
-
(2008)
A phase II trial of biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, interferon and digoxin in melanoma patients: Annual Meeting
-
-
Khan, M.I.1
Laber, D.2
Chesney, J.3
-
49
-
-
81055149905
-
Digitoxin-induced cytotoxicity in cancer cells is mediated through distinct kinase and interferon signaling networks
-
Prassas I, Karagiannis GS, Batruch I, et al. Digitoxin-induced cytotoxicity in cancer cells is mediated through distinct kinase and interferon signaling networks. Mol Cancer Ther 2011; 10: 2083-93.
-
(2011)
Mol Cancer Ther
, vol.10
, pp. 2083-2093
-
-
Prassas, I.1
Karagiannis, G.S.2
Batruch, I.3
-
50
-
-
34547754022
-
Digitoxin as an anticancer agent with selectivity for cancer cells: Possible mechanisms involved
-
López-Lázaro M. Digitoxin as an anticancer agent with selectivity for cancer cells: possible mechanisms involved. Expert Opin Ther Targets 2007; 11: 1043-53.
-
(2007)
Expert Opin Ther Targets
, vol.11
, pp. 1043-1053
-
-
López-Lázaro, M.1
-
51
-
-
84864648362
-
Digitoxin and its analogs as novel cancer therapeutics
-
Elbaz HA, Stueckle TA, Tse W, et al. Digitoxin and its analogs as novel cancer therapeutics. Exp Hematol Oncol 2012; 1: 4.
-
(2012)
Exp Hematol Oncol
, vol.1
, pp. 4
-
-
Elbaz, H.A.1
Stueckle, T.A.2
Tse, W.3
-
52
-
-
33646699335
-
Oleandrin-mediated oxidative stress in human melanoma cells
-
Newman RA, Yang P, Hittelman WN, et al. Oleandrin-mediated oxidative stress in human melanoma cells. J Exp Ther Oncol 2006; 5: 167-81.
-
(2006)
J Exp Ther Oncol
, vol.5
, pp. 167-181
-
-
Newman, R.A.1
Yang, P.2
Hittelman, W.N.3
-
53
-
-
0034660878
-
Cardiac glycosides stimulate Ca2+ increases and apoptosis in androgen-independent, metastatic human prostate adenocarcinoma cells
-
McConkey DJ, Lin Y, Nutt LK, et al. Cardiac glycosides stimulate Ca2+ increases and apoptosis in androgen-independent, metastatic human prostate adenocarcinoma cells. Cancer Res 2000; 60: 3807-12.
-
(2000)
Cancer Res
, vol.60
, pp. 3807-3812
-
-
McConkey, D.J.1
Lin, Y.2
Nutt, L.K.3
-
54
-
-
33846470475
-
Cardiac glycoside induces cell death via FasL by activating calcineurin and NF-AT, but apoptosis initially proceeds through activation of caspases
-
Raghavendra PB, Sreenivasan Y, Ramesh GT, Manna SK. Cardiac glycoside induces cell death via FasL by activating calcineurin and NF-AT, but apoptosis initially proceeds through activation of caspases. Apoptosis 2007; 12: 307-18.
-
(2007)
Apoptosis
, vol.12
, pp. 307-318
-
-
Raghavendra, P.B.1
Sreenivasan, Y.2
Ramesh, G.T.3
Manna, S.K.4
-
55
-
-
33846188582
-
Oleandrin induces apoptosis in human, but not in murine cells: Dephosphorylation of Akt, expression of FasL, and alteration of membrane fluidity
-
Raghavendra PB, Sreenivasan Y, Manna SK. Oleandrin induces apoptosis in human, but not in murine cells: dephosphorylation of Akt, expression of FasL, and alteration of membrane fluidity. Mol Immunol 2007; 44: 2292-302.
-
(2007)
Mol Immunol
, vol.44
, pp. 2292-2302
-
-
Raghavendra, P.B.1
Sreenivasan, Y.2
Manna, S.K.3
-
56
-
-
36249023658
-
Autophagic cell death of human pancreatic tumor cells mediated by oleandrin, a lipidsoluble cardiac glycoside
-
Newman RA, Kondo Y, Yokoyama T, et al. Autophagic cell death of human pancreatic tumor cells mediated by oleandrin, a lipidsoluble cardiac glycoside. Integr Cancer Ther 2007; 6: 354-64.
-
(2007)
Integr Cancer Ther
, vol.6
, pp. 354-364
-
-
Newman, R.A.1
Kondo, Y.2
Yokoyama, T.3
-
57
-
-
33745013348
-
Phase 1 trial of Anvirzel in patients with refractory solid tumors
-
Mekhail T, Kaur H, Ganapathi R, et al. Phase 1 trial of Anvirzel in patients with refractory solid tumors. Invest New Drugs 2006; 24: 423-27.
-
(2006)
Invest New Drugs
, vol.24
, pp. 423-427
-
-
Mekhail, T.1
Kaur, H.2
Ganapathi, R.3
-
58
-
-
84938690353
-
First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-β and p70s6k, in patients with advanced solid tumors
-
[Epub ahead of print]
-
Hong DS, Henary H, Falchook GS, et al. First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-β and p70s6k, in patients with advanced solid tumors. Invest New Drugs 2014 [Epub ahead of print].
-
(2014)
Invest New Drugs
-
-
Hong, D.S.1
Henary, H.2
Falchook, G.S.3
-
59
-
-
33644974357
-
The cardenolide UNBS1450 is able to deactivate nuclear factor kappaBmediated cytoprotective effects in human non-small cell lung cancer cells
-
Mijatovic T, Op De Beeck A, Van Quaquebeke E, et al. The cardenolide UNBS1450 is able to deactivate nuclear factor kappaBmediated cytoprotective effects in human non-small cell lung cancer cells. Mol Cancer Ther 2006; 5: 391-9.
-
(2006)
Mol Cancer Ther
, vol.5
, pp. 391-399
-
-
Mijatovic, T.1
Op De Beeck, A.2
Van Quaquebeke, E.3
-
60
-
-
20044369153
-
Identification of a novel cardenolide (2''-oxovoruscharin) from Calotropis procera and the hemisynthesis of novel derivatives displaying potent in vitro antitumor activities and high in vivo tolerance: Structure-activity relationship analyses
-
Van Quaquebeke E, Simon G, André A, et al. Identification of a novel cardenolide (2''-oxovoruscharin) from Calotropis procera and the hemisynthesis of novel derivatives displaying potent in vitro antitumor activities and high in vivo tolerance: structure-activity relationship analyses. J Med Chem 2005; 48: 849-56.
-
(2005)
J Med Chem
, vol.48
, pp. 849-856
-
-
Van Quaquebeke, E.1
Simon, G.2
André, A.3
-
61
-
-
34249825771
-
The alpha1 subunit of the sodium pump could represent a novel target to combat non-small cell lung cancers
-
Mijatovic T, Roland I, Van Quaquebeke E, et al. The alpha1 subunit of the sodium pump could represent a novel target to combat non-small cell lung cancers. J Pathol 2007; 212: 170-9.
-
(2007)
J Pathol
, vol.212
, pp. 170-179
-
-
Mijatovic, T.1
Roland, I.2
Van Quaquebeke, E.3
-
62
-
-
41749099092
-
Targeting the alpha 1 subunit of the sodium pump to combat glioblastoma cells
-
discussion 221-12
-
Lefranc F, Mijatovic T, Kondo Y, et al. Targeting the alpha 1 subunit of the sodium pump to combat glioblastoma cells. Neurosurgery 2008; 62: 211-21; discussion 221-12.
-
(2008)
Neurosurgery
, vol.62
, pp. 211-221
-
-
Lefranc, F.1
Mijatovic, T.2
Kondo, Y.3
-
63
-
-
70350080771
-
The sodium pump alpha1 sub-unit: A disease progression-related target for metastatic melanoma treatment
-
Mathieu V, Pirker C, Martin de Lassalle E, et al. The sodium pump alpha1 sub-unit: a disease progression-related target for metastatic melanoma treatment. J Cell Mol Med 2009; 13: 3960-72.
-
(2009)
J Cell Mol Med
, vol.13
, pp. 3960-3972
-
-
Mathieu, V.1
Pirker, C.2
Martin de Lassalle, E.3
-
64
-
-
49849100632
-
Nucleolus and c-Myc: Potential targets of cardenolide-mediated antitumor activity
-
Mijatovic T, De Nève N, Gailly P, et al. Nucleolus and c-Myc: potential targets of cardenolide-mediated antitumor activity. Mol Cancer Ther 2008; 7: 1285-96.
-
(2008)
Mol Cancer Ther
, vol.7
, pp. 1285-1296
-
-
Mijatovic, T.1
De Nève, N.2
Gailly, P.3
-
65
-
-
33744824903
-
Cardenolide-induced lysosomal membrane permeabilization demonstrates therapeutic benefits in experimental human non-small cell lung cancers
-
Mijatovic T, Mathieu V, Gaussin JF, et al. Cardenolide-induced lysosomal membrane permeabilization demonstrates therapeutic benefits in experimental human non-small cell lung cancers. Neoplasia 2006; 8: 402-12.
-
(2006)
Neoplasia
, vol.8
, pp. 402-412
-
-
Mijatovic, T.1
Mathieu, V.2
Gaussin, J.F.3
-
66
-
-
78549284246
-
UNBS1450, a steroid cardiac glycoside inducing apoptotic cell death in human leukemia cells
-
Juncker T, Cerella C, Teiten MH, et al. UNBS1450, a steroid cardiac glycoside inducing apoptotic cell death in human leukemia cells. Biochem Pharmacol 2011; 81: 13-23.
-
(2011)
Biochem Pharmacol
, vol.81
, pp. 13-23
-
-
Juncker, T.1
Cerella, C.2
Teiten, M.H.3
-
67
-
-
24744443929
-
Induction of apoptosis by Chan Su, a traditional Chinese medicine, in human bladder carcinoma T24 cells
-
Ko WS, Park TY, Park C, et al. Induction of apoptosis by Chan Su, a traditional Chinese medicine, in human bladder carcinoma T24 cells. Oncol Rep 2005; 14: 475-80.
-
(2005)
Oncol Rep
, vol.14
, pp. 475-480
-
-
Ko, W.S.1
Park, T.Y.2
Park, C.3
-
68
-
-
84902974693
-
Bufalin inhibited the growth of human osteosarcoma MG-63 cells via down-regulation of Bcl-2/Bax and triggering of the mitochondrial pathway
-
Wang D, Bi Z. Bufalin inhibited the growth of human osteosarcoma MG-63 cells via down-regulation of Bcl-2/Bax and triggering of the mitochondrial pathway. Tumour Biol 2014; 35: 4885-90.
-
(2014)
Tumour Biol
, vol.35
, pp. 4885-4890
-
-
Wang, D.1
Bi, Z.2
-
69
-
-
84901616419
-
Bufalin enhances TRAIL-induced apoptosis by redistributing death receptors in lipid rafts in breast cancer cells
-
Yan S, Qu X, Xu L, et al. Bufalin enhances TRAIL-induced apoptosis by redistributing death receptors in lipid rafts in breast cancer cells. Anticancer Drugs 2014; 25: 683-9.
-
(2014)
Anticancer Drugs
, vol.25
, pp. 683-689
-
-
Yan, S.1
Qu, X.2
Xu, L.3
-
70
-
-
84896517086
-
Bufalin is a potent smallmolecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1
-
Wang Y, Lonard DM, Yu Y, et al. Bufalin is a potent smallmolecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1. Cancer Res 2014; 74: 1506-17.
-
(2014)
Cancer Res
, vol.74
, pp. 1506-1517
-
-
Wang, Y.1
Lonard, D.M.2
Yu, Y.3
-
71
-
-
84896721859
-
Bufalin induces the interplay between apoptosis and autophagy in glioma cells through endoplasmic reticulum stress
-
Shen S, Zhang Y, Wang Z, et al. Bufalin induces the interplay between apoptosis and autophagy in glioma cells through endoplasmic reticulum stress. Int J Biol Sci 2014; 10: 212-24.
-
(2014)
Int J Biol Sci
, vol.10
, pp. 212-224
-
-
Shen, S.1
Zhang, Y.2
Wang, Z.3
-
72
-
-
58149229785
-
Efficacy and safety of gemcitabineoxaliplatin combined with huachansu in patients with advanced gallbladder carcinoma
-
Qin TJ, Zhao XH, Yun J, et al. Efficacy and safety of gemcitabineoxaliplatin combined with huachansu in patients with advanced gallbladder carcinoma. World J Gastroenterol 2008; 14: 5210-6.
-
(2008)
World J Gastroenterol
, vol.14
, pp. 5210-5216
-
-
Qin, T.J.1
Zhao, X.H.2
Yun, J.3
-
73
-
-
70449376872
-
Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer
-
Meng Z, Yang P, Shen Y, et al. Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. Cancer 2009; 115: 5309-18.
-
(2009)
Cancer
, vol.115
, pp. 5309-5318
-
-
Meng, Z.1
Yang, P.2
Shen, Y.3
-
74
-
-
84864377344
-
Prospective randomised evaluation of traditional Chinese medicine combined with chemotherapy: A randomised phase II study of wild toad extract plus gemcitabine in patients with advanced pancreatic adenocarcinomas
-
Meng Z, Garrett CR, Shen Y, et al. Prospective randomised evaluation of traditional Chinese medicine combined with chemotherapy: a randomised phase II study of wild toad extract plus gemcitabine in patients with advanced pancreatic adenocarcinomas. Br J Cancer 2012; 107: 411-6.
-
(2012)
Br J Cancer
, vol.107
, pp. 411-416
-
-
Meng, Z.1
Garrett, C.R.2
Shen, Y.3
-
75
-
-
0042732944
-
Structure-based design and synthesis of novel potent Na+, K+-ATPase inhibitors derived from a 5alpha, 14alpha-androstane scaffold as positive inotropic compounds
-
De Munari S, Cerri A, Gobbini M, et al. Structure-based design and synthesis of novel potent Na+, K+-ATPase inhibitors derived from a 5alpha, 14alpha-androstane scaffold as positive inotropic compounds. J Med Chem 2003; 46: 3644-54.
-
(2003)
J Med Chem
, vol.46
, pp. 3644-3654
-
-
De Munari, S.1
Cerri, A.2
Gobbini, M.3
-
76
-
-
49449108728
-
Novel analogues of istaroxime, a potent inhibitor of Na+, K+-ATPase: Synthesis and structure-activity relationship
-
Gobbini M, Armaroli S, Banfi L, et al. Novel analogues of istaroxime, a potent inhibitor of Na+, K+-ATPase: synthesis and structure-activity relationship. J Med Chem 2008; 51: 4601-8.
-
(2008)
J Med Chem
, vol.51
, pp. 4601-4608
-
-
Gobbini, M.1
Armaroli, S.2
Banfi, L.3
-
77
-
-
77953139706
-
Novel analogues of Istaroxime, a potent inhibitor of Na(+), K(+)-ATPase: Synthesis, structure-activity relationship and 3D-quantitative structure-activity relationship of derivatives at position 6 on the androstane scaffold
-
Gobbini M, Armaroli S, Banfi L, et al. Novel analogues of Istaroxime, a potent inhibitor of Na(+), K(+)-ATPase: Synthesis, structure-activity relationship and 3D-quantitative structure-activity relationship of derivatives at position 6 on the androstane scaffold. Bioorg Med Chem 2010; 18: 4275-99.
-
(2010)
Bioorg Med Chem
, vol.18
, pp. 4275-4299
-
-
Gobbini, M.1
Armaroli, S.2
Banfi, L.3
-
78
-
-
0036827948
-
Pharmacological profile of the novel inotropic agent (E, Z)-3-((2-aminoethoxy)imino)androstane-6, 17-dione hydrochloride (PST2744)
-
Micheletti R, Mattera GG, Rocchetti M, et al. Pharmacological profile of the novel inotropic agent (E, Z)-3-((2-aminoethoxy)imino)androstane-6, 17-dione hydrochloride (PST2744). J Pharmacol Exp Ther 2002; 303: 592-600.
-
(2002)
J Pharmacol Exp Ther
, vol.303
, pp. 592-600
-
-
Micheletti, R.1
Mattera, G.G.2
Rocchetti, M.3
-
79
-
-
70449090165
-
Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: A new promising treatment for acute heart failure syndromes?
-
Khan H, Metra M, Blair JE, et al. Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes? Heart Fail Rev 2009; 14: 277-87.
-
(2009)
Heart Fail Rev
, vol.14
, pp. 277-287
-
-
Khan, H.1
Metra, M.2
Blair, J.E.3
-
80
-
-
44449084777
-
Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: A randomized controlled trial in patients hospitalized with heart failure
-
Gheorghiade M, Blair JE, Filippatos GS, et al. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. J Am Coll Cardiol 2008; 51: 2276-85.
-
(2008)
J Am Coll Cardiol
, vol.51
, pp. 2276-2285
-
-
Gheorghiade, M.1
Blair, J.E.2
Filippatos, G.S.3
-
81
-
-
67049100043
-
Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: Results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: A Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial
-
Shah SJ, Blair JE, Filippatos GS, et al. Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial. Am Heart J 2009; 157: 1035-41.
-
(2009)
Am Heart J
, vol.157
, pp. 1035-1041
-
-
Shah, S.J.1
Blair, J.E.2
Filippatos, G.S.3
-
82
-
-
0018375632
-
Digoxin and hormone receptors
-
Cove DH, Barker GA. Digoxin and hormone receptors. Lancet 1979; 2: 204.
-
(1979)
Lancet
, vol.2
, pp. 204
-
-
Cove, D.H.1
Barker, G.A.2
-
83
-
-
84906319891
-
The Steroidal Na+/K+ ATPase Inhibitor 3-[(R)-3-Pyrrolidinyl]oxime Derivative (3-R-POD) Induces Potent Pro-Apoptotic Responses in Colonic Tumor Cells
-
Alkahtani SH. The Steroidal Na+/K+ ATPase Inhibitor 3-[(R)-3-Pyrrolidinyl]oxime Derivative (3-R-POD) Induces Potent Pro-Apoptotic Responses in Colonic Tumor Cells. Anticancer Res 2014; 34: 2967-71.
-
(2014)
Anticancer Res
, vol.34
, pp. 2967-2971
-
-
Alkahtani, S.H.1
-
84
-
-
84907175981
-
A steroidal Na+/K+ ATPase Inhibitor Triggers Pro-Apoptotic Signaling and Induces Apoptosis in Prostate and Lung Tumor Cells
-
[Epub ahead of print]
-
Honisch S, Alkahtani S, Kounenidakis M, et al. A steroidal Na+/K+ ATPase Inhibitor Triggers Pro-Apoptotic Signaling and Induces Apoptosis in Prostate and Lung Tumor Cells. Anticancer Agents Med Chem 2014 [Epub ahead of print].
-
(2014)
Anticancer Agents Med Chem
-
-
Honisch, S.1
Alkahtani, S.2
Kounenidakis, M.3
-
85
-
-
84869783143
-
Wedelolactone, a medicinal plant-derived coumestan, induces caspase-dependent apoptosis in prostate cancer cells via downregulation of PKCβ without inhibiting Akt
-
Sarveswaran S, Gautam SC, Ghosh J. Wedelolactone, a medicinal plant-derived coumestan, induces caspase-dependent apoptosis in prostate cancer cells via downregulation of PKCβ without inhibiting Akt. Int J Oncol 2012; 41: 2191-9.
-
(2012)
Int J Oncol
, vol.41
, pp. 2191-2199
-
-
Sarveswaran, S.1
Gautam, S.C.2
Ghosh, J.3
-
86
-
-
84877909949
-
Wedelolactone, a naturally occurring coumestan, enhances interferon-γ signaling through inhibiting STAT1 protein dephosphorylation
-
Chen Z, Sun X, Shen S, et al. Wedelolactone, a naturally occurring coumestan, enhances interferon-γ signaling through inhibiting STAT1 protein dephosphorylation. J Biol Chem 2013; 288: 14417-27.
-
(2013)
J Biol Chem
, vol.288
, pp. 14417-14427
-
-
Chen, Z.1
Sun, X.2
Shen, S.3
-
87
-
-
77952404297
-
Identification of hydroxyxanthones as Na/K-ATPase ligands
-
Zhang Z, Li Z, Tian J, et al. Identification of hydroxyxanthones as Na/K-ATPase ligands. Mol Pharmacol 2010; 77: 961-7.
-
(2010)
Mol Pharmacol
, vol.77
, pp. 961-967
-
-
Zhang, Z.1
Li, Z.2
Tian, J.3
-
88
-
-
84921990756
-
Gossypol enhances radiation induced autophagy in glioblastoma multiforme
-
[Epub ahead of print]
-
Keshmiri-Neghab H, Goliaei B, Nikoofar A. Gossypol enhances radiation induced autophagy in glioblastoma multiforme. Gen Physiol Biophys 2014 [Epub ahead of print].
-
(2014)
Gen Physiol Biophys
-
-
Keshmiri-Neghab, H.1
Goliaei, B.2
Nikoofar, A.3
-
89
-
-
84902210311
-
Gossypol Increases Expression of the Pro-apoptotic BH3-only Protein NOXA through a Novel Mechanism Involving Phospholipase A2, Cytoplasmic Calcium, and Endoplasmic Reticulum Stress
-
Soderquist RS, Danilov AV, Eastman A. Gossypol Increases Expression of the Pro-apoptotic BH3-only Protein NOXA through a Novel Mechanism Involving Phospholipase A2, Cytoplasmic Calcium, and Endoplasmic Reticulum Stress. J Biol Chem 2014; 289: 16190-16199.
-
(2014)
J Biol Chem
, vol.289
, pp. 16190-16199
-
-
Soderquist, R.S.1
Danilov, A.V.2
Eastman, A.3
-
90
-
-
84901188207
-
Glucocorticoid sensitisation in Mixed Lineage Leukaemiarearranged acute lymphoblastic leukaemia by the pan-BCL-2 family inhibitors gossypol and AT-101
-
Spijkers-Hagelstein JA, Schneider P, Pinhanços SM, et al. Glucocorticoid sensitisation in Mixed Lineage Leukaemiarearranged acute lymphoblastic leukaemia by the pan-BCL-2 family inhibitors gossypol and AT-101. Eur J Cancer 2014; 50: 1665-74.
-
(2014)
Eur J Cancer
, vol.50
, pp. 1665-1674
-
-
Spijkers-Hagelstein, J.A.1
Schneider, P.2
Pinhanços, S.M.3
-
91
-
-
84898474749
-
BH3-mimetic gossypol-induced autophagic cell death in mutant BRAF melanoma cells with high expression of p21Cipα.)
-
Jang GH, Lee M. BH3-mimetic gossypol-induced autophagic cell death in mutant BRAF melanoma cells with high expression of p21Cipα.. Life Sci 2014; 102: 41-48.
-
(2014)
Life Sci
, vol.102
, pp. 41-48
-
-
Jang, G.H.1
Lee, M.2
-
92
-
-
84890502480
-
Therapeutic potential of gossypol: An overview
-
Keshmiri-Neghab H, Goliaei B. Therapeutic potential of gossypol: an overview. Pharm Biol 2014; 52: 124-8.
-
(2014)
Pharm Biol
, vol.52
, pp. 124-128
-
-
Keshmiri-Neghab, H.1
Goliaei, B.2
-
93
-
-
84863981435
-
Evidence for a potential tumor suppressor role for the Na, K-ATPase beta1-subunit
-
Inge LJ, Rajasekaran SA, Yoshimoto K, et al. Evidence for a potential tumor suppressor role for the Na, K-ATPase beta1-subunit. Histol Histopathol 2008; 23: 459-67.
-
(2008)
Histol Histopathol
, vol.23
, pp. 459-467
-
-
Inge, L.J.1
Rajasekaran, S.A.2
Yoshimoto, K.3
-
94
-
-
84872746243
-
"The Lower Threshold" phenomenon in tumor cells toward endogenous digitalis-like compounds: Responsible for tumorigenesis?
-
Weidemann H. "The Lower Threshold" phenomenon in tumor cells toward endogenous digitalis-like compounds: Responsible for tumorigenesis? J Carcinog 2012; 11: 2.
-
(2012)
J Carcinog
, vol.11
, pp. 2
-
-
Weidemann, H.1
-
95
-
-
84867772337
-
Characterization of humaninduced pluripotent stem cell-derived cardiomyocytes: Bioenergetics and utilization in safety screening
-
Rana P, Anson B, Engle S, Will Y. Characterization of humaninduced pluripotent stem cell-derived cardiomyocytes: bioenergetics and utilization in safety screening. Toxicol Sci 2012; 130: 117-131.
-
(2012)
Toxicol Sci
, vol.130
, pp. 117-131
-
-
Rana, P.1
Anson, B.2
Engle, S.3
Will, Y.4
-
96
-
-
0037446091
-
Analysis of the Na, K-ATPase alpha-and beta-subunit expression profiles of bladder cancer using tissue microarrays
-
Espineda C, Seligson DB, James Ball W, et al. Analysis of the Na, K-ATPase alpha-and beta-subunit expression profiles of bladder cancer using tissue microarrays. Cancer 2003; 97: 1859-1868.
-
(2003)
Cancer
, vol.97
, pp. 1859-1868
-
-
Espineda, C.1
Seligson, D.B.2
James Ball, W.3
-
97
-
-
0025812383
-
Tissue-specific expression of Na, K-ATPase beta-subunit
-
Akopyanz NS, Broude NE, Bekman EP, et al. Tissue-specific expression of Na, K-ATPase beta-subunit. Does beta 2 expression correlate with tumorigenesis? FEBS Lett 1991; 289: 8-10.
-
(1991)
Does beta 2 expression correlate with tumorigenesis? FEBS Lett
, vol.289
, pp. 8-10
-
-
Akopyanz, N.S.1
Broude, N.E.2
Bekman, E.P.3
-
98
-
-
0032885002
-
Regulation of expression of Na+, K+-ATPase in androgen-dependent and androgen-independent prostate cancer
-
Blok LJ, Chang GT, Steenbeek-Slotboom M, et al. Regulation of expression of Na+, K+-ATPase in androgen-dependent and androgen-independent prostate cancer. Br J Cancer 1999; 81: 28-36.
-
(1999)
Br J Cancer
, vol.81
, pp. 28-36
-
-
Blok, L.J.1
Chang, G.T.2
Steenbeek-Slotboom, M.3
-
99
-
-
0032866353
-
Reduced expression of beta-subunit of Na, K-ATPase in human clear-cell renal cell carcinoma
-
Rajasekaran SA, Ball WJ, Bander NH, et al. Reduced expression of beta-subunit of Na, K-ATPase in human clear-cell renal cell carcinoma. J Urol 1999; 162: 574-580.
-
(1999)
J Urol
, vol.162
, pp. 574-580
-
-
Rajasekaran, S.A.1
Ball, W.J.2
Bander, N.H.3
-
100
-
-
9244251969
-
Identification and cloning of genes displaying elevated expression as a consequence of metastatic progression in human melanoma cells by rapid subtraction hybridization
-
Boukerche H, Su ZZ, Kang DC, Fisher PB. Identification and cloning of genes displaying elevated expression as a consequence of metastatic progression in human melanoma cells by rapid subtraction hybridization. Gene 2004; 343: 191-201.
-
(2004)
Gene
, vol.343
, pp. 191-201
-
-
Boukerche, H.1
Su, Z.Z.2
Kang, D.C.3
Fisher, P.B.4
-
101
-
-
1542373736
-
Repression of Na, KATPase beta1-subunit by the transcription factor snail in carcinoma
-
Espineda CE, Chang JH, Twiss J, et al. Repression of Na, KATPase beta1-subunit by the transcription factor snail in carcinoma. Mol Biol Cell 2004; 15: 1364-73.
-
(2004)
Mol Biol Cell
, vol.15
, pp. 1364-1373
-
-
Espineda, C.E.1
Chang, J.H.2
Twiss, J.3
-
102
-
-
1842737653
-
Up-regulation of Na(+), K(+)-ATPase alpha 3-isoform and down-regulation of the alpha1-isoform in human colorectal cancer
-
Sakai H, Suzuki T, Maeda M, et al. Up-regulation of Na(+), K(+)-ATPase alpha 3-isoform and down-regulation of the alpha1-isoform in human colorectal cancer. FEBS Lett 2004; 563: 151-4.
-
(2004)
FEBS Lett
, vol.563
, pp. 151-154
-
-
Sakai, H.1
Suzuki, T.2
Maeda, M.3
-
103
-
-
36749015141
-
Na, K-adenosine triphosphatase alpha1-subunit predicts survival of renal clear cell carcinoma
-
Seligson DB, Rajasekaran SA, Yu H, et al. Na, K-adenosine triphosphatase alpha1-subunit predicts survival of renal clear cell carcinoma. J Urol 2008; 179: 338-45.
-
(2008)
J Urol
, vol.179
, pp. 338-345
-
-
Seligson, D.B.1
Rajasekaran, S.A.2
Yu, H.3
-
104
-
-
79956070393
-
Immunohistochemical analyses of alpha1 and alpha3 Na+/K+-ATPase subunit expression in medulloblastomas
-
Suñol M, Cusi V, Cruz O, et al. Immunohistochemical analyses of alpha1 and alpha3 Na+/K+-ATPase subunit expression in medulloblastomas. Anticancer Res 2011; 31: 953-8.
-
(2011)
Anticancer Res
, vol.31
, pp. 953-958
-
-
Suñol, M.1
Cusi, V.2
Cruz, O.3
-
105
-
-
0028063457
-
Neu and ras initiate murine mammary tumors that share genetic markers generally absent in c-myc and int-2-initiated tumors
-
Morrison BW, Leder P. neu and ras initiate murine mammary tumors that share genetic markers generally absent in c-myc and int-2-initiated tumors. Oncogene 1994; 9: 3417-26.
-
(1994)
Oncogene
, vol.9
, pp. 3417-3426
-
-
Morrison, B.W.1
Leder, P.2
-
106
-
-
0034662757
-
The FXYD gene family of small ion transport regulators or channels: CDNA sequence, protein signature sequence, and expression
-
Sweadner KJ, Rael E. The FXYD gene family of small ion transport regulators or channels: cDNA sequence, protein signature sequence, and expression. Genomics 2000; 68: 41-56.
-
(2000)
Genomics
, vol.68
, pp. 41-56
-
-
Sweadner, K.J.1
Rael, E.2
-
107
-
-
0033899865
-
Differentially expressed genes in two LNCaP prostate cancer cell lines reflecting changes during prostate cancer progression
-
Vaarala MH, Porvari K, Kyllönen A, Vihko P. Differentially expressed genes in two LNCaP prostate cancer cell lines reflecting changes during prostate cancer progression. Lab Invest 2000; 80: 1259-68.
-
(2000)
Lab Invest
, vol.80
, pp. 1259-1268
-
-
Vaarala, M.H.1
Porvari, K.2
Kyllönen, A.3
Vihko, P.4
-
108
-
-
3843134200
-
Up-regulated expression of the MAT-8 gene in prostate cancer and its siRNA-mediated inhibition of expression induces a decrease in proliferation of human prostate carcinoma cells
-
Grzmil M, Voigt S, Thelen P, et al. Up-regulated expression of the MAT-8 gene in prostate cancer and its siRNA-mediated inhibition of expression induces a decrease in proliferation of human prostate carcinoma cells. Int J Oncol 2004; 24: 97-105.
-
(2004)
Int J Oncol
, vol.24
, pp. 97-105
-
-
Grzmil, M.1
Voigt, S.2
Thelen, P.3
-
109
-
-
27944509575
-
FXYD3 is overexpressed in pancreatic ductal adenocarcinoma and influences pancreatic cancer cell growth
-
Kayed H, Kleeff J, Kolb A, et al. FXYD3 is overexpressed in pancreatic ductal adenocarcinoma and influences pancreatic cancer cell growth. Int J Cancer 2006; 118: 43-54.
-
(2006)
Int J Cancer
, vol.118
, pp. 43-54
-
-
Kayed, H.1
Kleeff, J.2
Kolb, A.3
-
110
-
-
73549112431
-
Down-regulation of FXYD3 expression in human lung cancers: Its mechanism and potential role in carcinogenesis
-
Okudela K, Yazawa T, Ishii J, et al. Down-regulation of FXYD3 expression in human lung cancers: its mechanism and potential role in carcinogenesis. Am J Pathol 2009; 175: 2646-56.
-
(2009)
Am J Pathol
, vol.175
, pp. 2646-2656
-
-
Okudela, K.1
Yazawa, T.2
Ishii, J.3
-
111
-
-
77954037634
-
Expression and significance of FXYD-3 protein in gastric adenocarcinoma
-
Zhu ZL, Zhao ZR, Zhang Y, et al. Expression and significance of FXYD-3 protein in gastric adenocarcinoma. Dis Markers 2010; 28: 63-9.
-
(2010)
Dis Markers
, vol.28
, pp. 63-69
-
-
Zhu, Z.L.1
Zhao, Z.R.2
Zhang, Y.3
-
112
-
-
79952925205
-
FXYD3: A Promising Biomarker for Urothelial Carcinoma
-
Zhang Z, Pang ST, Kasper KA, et al. FXYD3: A Promising Biomarker for Urothelial Carcinoma. Biomark Insights 2011; 6: 17-26.
-
(2011)
Biomark Insights
, vol.6
, pp. 17-26
-
-
Zhang, Z.1
Pang, S.T.2
Kasper, K.A.3
-
113
-
-
0037441643
-
Dysadherin overexpression in pancreatic ductal adenocarcinoma reflects tumor aggressiveness: Relationship to e-cadherin expression
-
Shimamura T, Sakamoto M, Ino Y, et al. Dysadherin overexpression in pancreatic ductal adenocarcinoma reflects tumor aggressiveness: relationship to e-cadherin expression. J Clin Oncol 2003; 21: 659-67.
-
(2003)
J Clin Oncol
, vol.21
, pp. 659-667
-
-
Shimamura, T.1
Sakamoto, M.2
Ino, Y.3
-
114
-
-
0037430034
-
Prognostic significance of dysadherin expression in advanced colorectal carcinoma
-
Aoki S, Shimamura T, Shibata T, et al. Prognostic significance of dysadherin expression in advanced colorectal carcinoma. Br J Cancer 2003; 88: 726-32.
-
(2003)
Br J Cancer
, vol.88
, pp. 726-732
-
-
Aoki, S.1
Shimamura, T.2
Shibata, T.3
-
115
-
-
0141787918
-
Dysadherin: Expression and clinical significance in thyroid carcinoma
-
Sato H, Ino Y, Miura A, et al. Dysadherin: expression and clinical significance in thyroid carcinoma. J Clin Endocrinol Metab 2003; 88: 4407-12.
-
(2003)
J Clin Endocrinol Metab
, vol.88
, pp. 4407-4412
-
-
Sato, H.1
Ino, Y.2
Miura, A.3
-
116
-
-
33645218212
-
Dysadherin expression in head and neck squamous cell carcinoma: Association with lymphangiogenesis and prognostic significance
-
Kyzas PA, Stefanou D, Batistatou A, et al. Dysadherin expression in head and neck squamous cell carcinoma: association with lymphangiogenesis and prognostic significance. Am J Surg Pathol 2006; 30: 185-93.
-
(2006)
Am J Surg Pathol
, vol.30
, pp. 185-193
-
-
Kyzas, P.A.1
Stefanou, D.2
Batistatou, A.3
-
117
-
-
79952987885
-
Significance of dysadherin and E-cadherin expression in differentiated-type gastric carcinoma with submucosal invasion
-
Maehata Y, Hirahashi M, Aishima S, et al. Significance of dysadherin and E-cadherin expression in differentiated-type gastric carcinoma with submucosal invasion. Hum Pathol 2011; 42: 558-67.
-
(2011)
Hum Pathol
, vol.42
, pp. 558-567
-
-
Maehata, Y.1
Hirahashi, M.2
Aishima, S.3
-
118
-
-
79952032469
-
Comparison of the dysadherin and E-cadherin expression in primary lung cancer and metastatic sites
-
Mitselou A, Batistatou A, Nakanishi Y, et al. Comparison of the dysadherin and E-cadherin expression in primary lung cancer and metastatic sites. Histol Histopathol 2010; 25: 1257-67.
-
(2010)
Histol Histopathol
, vol.25
, pp. 1257-1267
-
-
Mitselou, A.1
Batistatou, A.2
Nakanishi, Y.3
-
119
-
-
80054976328
-
A monoclonal antibody against human FXYD6
-
Liu J, Zhou N, Zhang X. A monoclonal antibody against human FXYD6. Hybridoma (Larchmt) 2011; 30: 487-90.
-
(2011)
Hybridoma (Larchmt)
, vol.30
, pp. 487-490
-
-
Liu, J.1
Zhou, N.2
Zhang, X.3
-
120
-
-
84890341993
-
FXYD6 is a new biomarker of cholangiocarcinoma
-
Chen X, Sun M, Hu Y, et al. FXYD6 is a new biomarker of cholangiocarcinoma. Oncol Lett 2014; 7: 393-8.
-
(2014)
Oncol Lett
, vol.7
, pp. 393-398
-
-
Chen, X.1
Sun, M.2
Hu, Y.3
-
121
-
-
84904196645
-
FXYD6: A novel therapeutic target toward hepatocellular carcinoma
-
Gao Q, Chen X, Duan H, et al. FXYD6: a novel therapeutic target toward hepatocellular carcinoma. Protein Cell 2014; 5: 532-43.
-
(2014)
Protein Cell
, vol.5
, pp. 532-543
-
-
Gao, Q.1
Chen, X.2
Duan, H.3
-
122
-
-
84925948656
-
-
May 29-June 2, Orlando, 2009; (ASCO) ASoCO, Vol, 27: pp suppl; abstr e19077
-
Kayali F, Janjua MA, Laber DA, et al. Phase II trial of second-line erlotinib and digoxin in patients with non-small cell lung cancer (NSCLC): Annual Meeting, May 29-June 2, Orlando, 2009; (ASCO) ASoCO, Vol. 27: 2009; pp suppl; abstr e19077.
-
(2009)
Phase II trial of second-line erlotinib and digoxin in patients with non-small cell lung cancer (NSCLC): Annual Meeting
-
-
Kayali, F.1
Janjua, M.A.2
Laber, D.A.3
-
123
-
-
84925948655
-
-
2013 ASCO Annual Meeting: Annual Meeting, May 31-June 4, Chicago, 2013; (ASCO) ASoCO, Vol. 31: pp suppl; abstr 5061
-
Lin J, Hoffman-Censits JH, Duffy D, et al. A pilot phase II study of digoxin in patients with recurrent prostate cancer as evident by a rising PSA. 2013 ASCO Annual Meeting: Annual Meeting, May 31-June 4, Chicago, 2013; (ASCO) ASoCO, Vol. 31: 2013; pp suppl; abstr 5061.
-
(2013)
A pilot phase II study of digoxin in patients with recurrent prostate cancer as evident by a rising PSA
-
-
Lin, J.1
Hoffman-Censits, J.H.2
Duffy, D.3
|